
|Videos|May 26, 2017
Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors
Author(s)Jonathan R. Strosberg, MD
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).
Advertisement
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).
After years of everolimus (Afinitor) and metastin analogs, the field is in a stage of expansion, says Strosberg. Agents such as telotristat ethyl (Xermelo) are signifying that new drugs—although niche—are signaling advancement in the treatment of NETs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5




































